Privacy Policy
In the case of the most prevalent type of primary immunodeficiency (PI), which is antibody deficiencies, the standard treatment involves lifelong immunoglobulin replacement therapy. There are two commonly employed methods for administering immunoglobulin: subcutaneous (Sub-Q Ig) and intravenous (IVIG). Intravenous immunoglobulin (IVIG) can be administered in sizable, less frequent doses, offering rapid effectiveness while circumventing the potential side effects linked to substantial subcutaneous injections.
The beneficial impacts of intravenous immunoglobulin (IVIG) in preventing primary immunodeficiency syndromes have been firmly established. Properly applying IVIG in the treatment of primary immunodeficiency (PI) helps maintain organ function, enhances quality of life, averts infection-related fatalities, and extends the lifespan of patients. The ultimate objective of IVIG therapy is to minimize infections in patients as much as possible.
For more details, please refer to our Frequently Asked Questions (FAQs) about Primary Immunodeficiency provided below: